Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REVERSAL is a family of injectable biostimulators developed by Koru Pharmaceuticals for aesthetic skin and soft-tissue rejuvenation. The product line includes the original REVERSAL (a hybrid of polylactic acid and hyaluronic acid), REVERSAL Neo (high-purity PLLA), and REVERSAL Dual (a dual-vial PLLA and HA system). These products function by inducing a controlled biological response that stimulates fibroblasts to produce endogenous collagen, leading to improved skin elasticity, volume restoration, and wrinkle reduction. The inclusion of hyaluronic acid provides immediate hydration and volumization, while the polylactic acid component ensures long-term structural improvement through tissue regeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on REVERSAL.